ReviewCurrent pharmaceutical design2013

Central actions of somatostatin-28 and oligosomatostatin agonists to prevent components of the endocrine, autonomic and visceral responses to stress through interaction with different somatostatin receptor subtypes.

Andreas Stengel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.